US equities |
NVDA $239.88 ▲+0.41% SPCX $172.85 ▲+1.03% MU $1,065.56 ▲+0.15% MRVL $284.19 ▲+4.77% AMD $654.38 ▲+3.58% INTC $114.11 ▼-1.79% SNDK $1,673.88 ▼-1.78% AVGO $378.91 ▲+4.52%
FinancialContent

Latest News about Spinal Muscular Atrophy

Recent news which mentions Spinal Muscular Atrophy

Scholar Rock To Highlight Apitegromab Data From Ambulatory Cohort In Muscular Dystrophy
Tickers SRRK
Tags Health Care Briefs Phase 2 Trial
From Benzinga
Scholar Rock Outlines Pivotal Apitegromab Trial Design In Spinal Muscular Atrophy Patients
Tickers SRRK
Tags Small Cap Briefs Health Care
From Benzinga
Roche Builds Case For Evrysdi Benefits In Younger Spinal Muscular Atrophy Patients
Tickers RHHBF RHHBY RHHVF
Tags Health Care Briefs Biotech
From Benzinga
Biogen Launches High-Dose Spinraza Trial In Evrysdi Treated Patients: What You Need To Know
Tickers BIIB RHHBF RHHBY RHHVF
Tags RHHVF News Market News
From Benzinga